{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:57:53Z","timestamp":1788836273932,"version":"build-2803163510"},"reference-count":25,"publisher":"Centers for Disease Control and Prevention (CDC)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emerg. Infect. Dis."],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.3201\/eid3008.240541","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T03:13:11Z","timestamp":1722309191000},"source":"Crossref","is-referenced-by-count":4,"title":["Potential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance"],"prefix":"10.3201","volume":"30","author":[{"given":"C. Finn","family":"McQuaid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa S.","family":"Ryckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas A.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily A.","family":"Kendall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1822","reference":[{"key":"key-10.3201\/eid3008.240541-202407101103-R1","unstructured":"World Health Organization. Global tuberculosis report 2023. 2023 [cited 2024 Apr 12]. https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2023"},{"key":"key-10.3201\/eid3008.240541-202407101103-R2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S2213-2600(23)00389-2","article-title":"Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.","volume":"12","author":"Nyang\u2019wa","year":"2024","journal-title":"Lancet Respir Med"},{"key":"key-10.3201\/eid3008.240541-202407101103-R3","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/s41591-024-02840-y","article-title":"Restocking the tuberculosis drug arsenal.","volume":"30","author":"Nuermberger","year":"2024","journal-title":"Nat Med"},{"key":"key-10.3201\/eid3008.240541-202407101103-R4","unstructured":"Treatment Action Group. Pipeline report 2023: tuberculosis treatment. 2023 [cited 2024 Apr 12]. https:\/\/www.treatmentactiongroup.org\/wp-content\/uploads\/2024\/03\/pipeline_TB_Treatment_2023_final.pdf"},{"key":"key-10.3201\/eid3008.240541-202407101103-R5","unstructured":"World Health Organization. Target regimen profiles for tuberculosis treatment, 2023 update. 2023 [cited 2024 Apr 14]. https:\/\/www.who.int\/publications\/i\/item\/9789240081512"},{"key":"key-10.3201\/eid3008.240541-202407101103-R6","doi-asserted-by":"publisher","first-page":"e0230808","DOI":"10.1371\/journal.pone.0230808","article-title":"The potential deployment of a pan-tuberculosis drug regimen in India: A modelling analysis.","volume":"15","author":"Arinaminpathy","year":"2020","journal-title":"PLoS One"},{"key":"key-10.3201\/eid3008.240541-202407101103-R7","doi-asserted-by":"publisher","first-page":"100350","DOI":"10.1016\/j.jctube.2023.100350","article-title":"Mind the gap. Rolling out new drug resistant tuberculosis regimens with limited diagnostic tools.","volume":"32","author":"Saluzzo","year":"2023","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"key-10.3201\/eid3008.240541-202407101103-R8","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"ZeNix Trial Team. Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis.","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid3008.240541-202407101103-R9","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-week, all-oral regimen for rifampin-resistant tuberculosis.","volume":"387","author":"Nyang\u2019wa","year":"2022","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid3008.240541-202407101103-R10","unstructured":"Foundation for the National Institutes of Health. PAN-TB, Project to Accelerate New Treatments for Tuberculosis. 2023 [cited 2024 Apr 11]. https:\/\/fnih.org\/our-programs\/pan-tb-project-to-accelerate-new-treatments-for-tuberculosis"},{"key":"key-10.3201\/eid3008.240541-202407101103-R11","unstructured":"Alliance TB. TB Alliance launches five-country phase 2 clinical trial evaluating next-generation tb drug. 2023 [cited 2024 Apr 11]. https:\/\/www.tballiance.org\/news\/tb-alliance-launches-five-country-phase-2-clinical-trial-evaluating-next-generation-tb-drug-0#:~:text=%E2%80%9CA%20'universal'%20TB%20medicine,and%20CEO%20of%20TB%20Alliance"},{"key":"key-10.3201\/eid3008.240541-202407101103-R12","doi-asserted-by":"publisher","first-page":"e972","DOI":"10.1016\/S2666-5247(23)00172-6","article-title":"Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study.","volume":"4","author":"Derendinger","year":"2023","journal-title":"Lancet Microbe"},{"key":"key-10.3201\/eid3008.240541-202407101103-R13","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment\u2014 drug-resistant tuberculosis treatment, 2022 update [cited 2024 Apr 8]. https:\/\/www.who.int\/publications\/i\/item\/9789240063129"},{"key":"key-10.3201\/eid3008.240541-202407101103-R14","doi-asserted-by":"publisher","first-page":"e995","DOI":"10.1016\/S2214-109X(24)00088-3","article-title":"Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis.","volume":"12","author":"Ryckman","year":"2024","journal-title":"Lancet Glob Health"},{"key":"key-10.3201\/eid3008.240541-202407101103-R15","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1093\/ije\/dyr058","article-title":"The incubation period distribution of tuberculosis estimated with a molecular epidemiological approach.","volume":"40","author":"Borgdorff","year":"2011","journal-title":"Int J Epidemiol"},{"key":"key-10.3201\/eid3008.240541-202407101103-R16","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/tmi.13485","article-title":"National tuberculosis prevalence surveys in Africa, 2008-2016: an overview of results and lessons learned.","volume":"25","author":"Law","year":"2020","journal-title":"Trop Med Int Health"},{"key":"key-10.3201\/eid3008.240541-202407101103-R17","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/tmi.12534","article-title":"National tuberculosis prevalence surveys in Asia, 1990-2012: an overview of results and lessons learned.","volume":"20","author":"Onozaki","year":"2015","journal-title":"Trop Med Int Health"},{"key":"key-10.3201\/eid3008.240541-202407101103-R18","doi-asserted-by":"publisher","first-page":"e2221186120","DOI":"10.1073\/pnas.2221186120","article-title":"Reevaluating progression and pathways following Mycobacterium tuberculosis infection within the spectrum of tuberculosis.","volume":"120","author":"Horton","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key-10.3201\/eid3008.240541-202407101103-R19","doi-asserted-by":"publisher","first-page":"e00479","DOI":"10.1128\/AAC.00479-20","article-title":"A multimethod, multicountry evaluation of breakpoints for bedaquiline resistance determination.","volume":"64","author":"Ismail","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.3201\/eid3008.240541-202407101103-R20","doi-asserted-by":"publisher","first-page":"e3391","DOI":"10.1093\/cid\/ciaa1002","article-title":"Reduced susceptibility of Mycobacterium tuberculosis to bedaquiline during antituberculosis treatment and its correlation with clinical outcomes in China.","volume":"73","author":"Liu","year":"2021","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid3008.240541-202407101103-R21","doi-asserted-by":"publisher","first-page":"2300639","DOI":"10.1183\/13993003.00639-2023","article-title":"Baseline and treatment-emergent bedaquiline resistance in drug-resistant tuberculosis: a systematic review and meta-analysis.","volume":"62","author":"Perumal","year":"2023","journal-title":"Eur Respir J"},{"key":"key-10.3201\/eid3008.240541-202407101103-R22","doi-asserted-by":"publisher","first-page":"e0002283","DOI":"10.1371\/journal.pgph.0002283","article-title":"Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid.","volume":"3","author":"Timm","year":"2023","journal-title":"PLOS Glob Public Health"},{"key":"key-10.3201\/eid3008.240541-202407101103-R23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jiph.2023.11.018","article-title":"The emerging threat of fluroquinolone-, bedaquiline-, and linezolid-resistant Mycobacterium tuberculosis in China: Observations on surveillance data.","volume":"17","author":"Li","year":"2024","journal-title":"J Infect Public Health"},{"key":"key-10.3201\/eid3008.240541-202407101103-R24","doi-asserted-by":"publisher","first-page":"2100621","DOI":"10.1183\/13993003.00621-2021","article-title":"Emergence of bedaquiline resistance in a high tuberculosis burden country.","volume":"59","author":"Chesov","year":"2022","journal-title":"Eur Respir J"},{"key":"key-10.3201\/eid3008.240541-202407101103-R25","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1093\/cid\/ciu572","article-title":"Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis.","volume":"59","author":"Cegielski","year":"2014","journal-title":"Clin Infect Dis"}],"container-title":["Emerging Infectious Diseases"],"original-title":[],"link":[{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/30\/8\/24-0541_article","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T18:38:33Z","timestamp":1732905513000},"score":1,"resource":{"primary":{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/30\/8\/24-0541_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"URL":"https:\/\/doi.org\/10.3201\/eid3008.240541","relation":{},"ISSN":["1080-6040","1080-6059"],"issn-type":[{"value":"1080-6040","type":"print"},{"value":"1080-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]}}}